zoledronic acid has been researched along with Paraneoplastic Syndromes in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Colak, U; Hatun, S; Kayserili, H; Mutlu, GY; Sozmen, BO; Yucel, EB | 1 |
| Eltze, E; Zimmer, V | 1 |
| Clark, SL; Nystrom, EM | 1 |
| Tao, H; Wang, M; Wang, Y; Wang, Z; Yu, X | 1 |
1 trial(s) available for zoledronic acid and Paraneoplastic Syndromes
| Article | Year |
|---|---|
Clinical significance of zoledronic acid and strontium-89 in patients with asymptomatic bone metastases from non-small-cell lung cancer.
Topics: Adult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Diphosphonates; Double-Blind Method; Female; Fractures, Bone; Humans; Hypercalcemia; Imidazoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paraneoplastic Syndromes; Spinal Cord Compression; Strontium; Zoledronic Acid | 2013 |
3 other study(ies) available for zoledronic acid and Paraneoplastic Syndromes
| Article | Year |
|---|---|
Zoledronate-responsive calcitriol-mediated hypercalcemia in a 5-year-old case with squamous cell carcinoma on the background of xeroderma pigmentosum.
Topics: Bone Density Conservation Agents; Calcitriol; Carcinoma, Squamous Cell; Child, Preschool; Humans; Hypercalcemia; Male; Paraneoplastic Syndromes; Prognosis; Xeroderma Pigmentosum; Zoledronic Acid | 2019 |
Parathyroid Hormone-Related Peptide (PTHrp)-Secreting Liver Metastatic Large-Cell Neuroendocrine Carcinoma of the Sigmoid Colon.
Topics: Aged; Biopsy; Bone Density Conservation Agents; Carcinoma, Neuroendocrine; Colon, Sigmoid; Colonic Neoplasms; Colonoscopy; Humans; Hypercalcemia; Liver Neoplasms; Male; Neoplasm Grading; Neoplasm Staging; Paraneoplastic Syndromes; Parathyroid Hormone-Related Protein; Tomography, X-Ray Computed; Treatment Outcome; Zoledronic Acid | 2021 |
A Case of Severe, Prolonged, Refractory Hypophosphatemia After Zoledronic Acid Administration.
Topics: Bone Density Conservation Agents; Diphosphonates; Humans; Hypercalcemia; Hypophosphatemia; Imidazoles; Male; Middle Aged; Paraneoplastic Syndromes; Zoledronic Acid | 2016 |